India is considered endemic cholera country. When looked at the national level, economic burden due to cholera treatment, loss of income due to inability to work and death is estimated to be more than $830 million in US$2015. This does not account for the larger economic loss related to export and tourism Industry. The National Biopharma Mission is committed to support development of vaccine candidates for cholera.
|
Name of grantee |
Development Phase Supported |
Environmental and Health Risk Management Plan (EHRMP) |
|
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) and Translational Health Science and Technology Institute (THSTI) |
Technology transfer and GMP production of batches |
|